A96: Arenaviral hemorrhagic fever
ICD-10 A96 is a billable code used to indicate a diagnosis of a96: arenaviral hemorrhagic fever.
Arenaviral hemorrhagic fever is a severe viral illness caused by arenaviruses, which are primarily transmitted through contact with infected rodents or their excreta. The disease is characterized by fever, hemorrhagic manifestations, and multi-organ involvement. Symptoms typically begin with a sudden onset of fever, malaise, and myalgia, followed by gastrointestinal symptoms such as nausea, vomiting, and abdominal pain. As the disease progresses, patients may develop bleeding tendencies, including petechiae, purpura, and gastrointestinal bleeding. The condition can lead to severe complications, including shock and organ failure, particularly in immunocompromised individuals. Arenaviral infections are endemic in certain regions, particularly in parts of Africa and South America, making travel history crucial for diagnosis. Laboratory confirmation is essential, often requiring serological tests or PCR to identify the specific arenavirus responsible for the infection. Given the potential for outbreaks and the severity of the disease, prompt recognition and reporting are critical for public health management.
Detailed travel history, symptom onset, and laboratory results.
Patients presenting with fever and bleeding after travel to endemic areas.
Consideration of co-infections and differential diagnoses is crucial.
Immediate assessment of symptoms and travel history.
Patients with acute febrile illness and potential exposure to arenaviruses.
Rapid identification and isolation protocols may be necessary.
Used for confirming arenavirus infection in patients with suspected hemorrhagic fever.
Document the reason for testing and any relevant clinical findings.
Infectious disease specialists should ensure proper specimen handling and testing protocols.
Common symptoms include fever, malaise, myalgia, gastrointestinal symptoms, and bleeding tendencies such as petechiae and purpura.
Diagnosis is made based on clinical presentation, travel history to endemic areas, and laboratory confirmation through serological tests or PCR.
